Summary & Overview

Urethral Procedures with CC/MCC: Inpatient Reimbursement Overview

DRG 671 encompasses inpatient admissions for urethral procedures when a Complication or Comorbidity or Major Complication or Comorbidity is present, covering procedures such as urethral dilation, urethrotomy, and reconstructive operations. This Diagnosis-Related Group matters for inpatient reimbursement because the presence of Complication or Comorbidity or Major Complication or Comorbidity affects payment classification and resource intensity for Centers for Medicare & Medicaid Services hospital payments.

Urethral Procedures with CC/MCCDRG Urethral Procedures with CC/MCCDRG 671Diagnosis-Related GroupInpatient ReimbursementMedicareUrologyUrethral dilationUrethrotomyReconstructive urology

DRG 671 Overview

DRG 671 covers inpatient admissions for urethral procedures performed for a range of urologic conditions when a Complication or Comorbidity or Major Complication or Comorbidity is present. It includes operative interventions on the urethra such as dilations, urethrotomies, and reconstructive procedures associated with increased resource use. This Diagnosis-Related Group matters for Medicare payment because presence of Complication or Comorbidity or Major Complication or Comorbidity influences relative reimbursement and hospital case mix classification. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus the inpatient payment grouping.

Clinical Trials

Acute procedural optimization trials: studies comparing perioperative techniques and immediate postoperative protocols for patients undergoing urethral procedures complicated by comorbid conditions (for example, those with infection, bleeding risk, or acute urinary retention). These trials enroll inpatients scheduled for urethral dilation, endoscopic urethrotomy, or reconstruction with concomitant CC/MCC-level diagnoses to evaluate metrics such as procedural success, intraoperative complications, need for reintervention, and length of stay. Results inform care pathways and resource use, helping providers reduce complications and payers anticipate hospitalization costs tied to procedure-related adverse events and readmissions.
Comparative effectiveness studies of surgical approaches and device use in complex urethral disease: randomized or pragmatic cohort studies that compare different surgical techniques (open repair vs. endoscopic approaches) or adjunctive technologies (e.g., grafts, stents, or catheter strategies) in patients with significant comorbidities or secondary conditions recorded as CC/MCC. These studies focus on midterm outcomes such as stricture recurrence, functional urinary outcomes, complication rates, and need for additional inpatient stays, targeting populations such as older adults, patients with prior pelvic surgery, or those with infection/bleeding risks. Findings help clinicians select procedures that balance effectiveness and safety for high-risk inpatients, and help payers evaluate cost-effectiveness across approaches that drive DRG resource intensity.
Post-discharge outcomes and care coordination research: observational and interventional studies examining transitions of care, early outpatient follow-up, urinary catheter management, and prevention of readmission among patients discharged after urethral procedures who had CC/MCC-level complications. These investigations follow cohorts for 30–90 days to assess readmission drivers, wound or urinary tract infections, catheter-related problems, and patient-reported functional recovery, often testing care bundle interventions or enhanced discharge planning. This research is critical for providers to implement protocols that reduce complications and for payers to identify strategies that lower costly readmissions and post-acute care utilization associated with this DRG.

Related Codes

669-TRANSURETHRAL-PROCEDURES-WITH-CC

Transurethral Procedures with CC: Inpatient Reimbursement Overview

684-RENAL-FAILURE-WITHOUT-CC-MCC

Renal Failure without CC/MCC: Inpatient Reimbursement Overview

693-URINARY-STONES-WITH-MCC

Urinary Stones with MCC: Inpatient Reimbursement Overview

675-OTHER-KIDNEY-AND-URINARY-TRACT-PROCEDURES-WITHOUT-CC-MCC

Other Kidney and Urinary Tract Procedures without CC/MCC: Inpatient Reimbursement Overview

699-OTHER-KIDNEY-AND-URINARY-TRACT-DIAGNOSES-WITH-CC

Other Kidney and Urinary Tract Diagnoses with CC: Inpatient Reimbursement Overview

668-TRANSURETHRAL-PROCEDURES-WITH-MCC

Transurethral Procedures with MCC: Inpatient Reimbursement Overview

667-PROSTATECTOMY-WITHOUT-CC-MCC

Prostatectomy without CC/MCC: Inpatient Reimbursement Overview

689-KIDNEY-AND-URINARY-TRACT-INFECTIONS-WITH-MCC

Kidney and Urinary Tract Infections with MCC: Inpatient Reimbursement Overview

655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

683-RENAL-FAILURE-WITH-CC

Renal Failure with CC: Inpatient Reimbursement Overview

Showing 1–10 of 41

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.